Inotrem S.A. is betting that a companion diagnostic can help its TREM1 inhibitors tamp down inflammation in the right sepsis patients and improve its odds of success in an indication where the only approved drug was pulled from the market three years ago.

Sepsis is a systematic inflammatory response most often triggered by severe bacterial infection. A major challenge to treatment is the immune response itself, which is both toxic to the host and necessary to combat the infection. To improve survival, a treatment must strike a delicate balance between the two.